• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三种针对不同 PSMA 表位的构象抗体是前列腺癌有前途的诊断和治疗工具。

Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.

机构信息

Department of Urology, Experimental Urology, University Hospital Freiburg, Freiburg, Germany.

出版信息

Prostate. 2010 Apr 1;70(5):562-9. doi: 10.1002/pros.21090.

DOI:10.1002/pros.21090
PMID:19938014
Abstract

BACKGROUND

The prostate specific membrane antigen (PSMA) represents an attractive antigen for antibody-based diagnostic and therapeutic intervention in prostate cancer, since it is highly restricted to the prostate and overexpressed in all tumor stages. The present work describes the in vitro characterization of the three anti-PSMA monoclonal antibodies (mAbs) 3/A12, 3/E7, and 3/F11 in comparison to the mAb J591.

METHODS

The mAbs were tested for saturation and competitive binding on C4-2 prostate cancer cells by flow cytometry. Immunohistochemical staining was conducted on frozen prostate normal and cancer tissues as well as on lymph node metastases. Similarly, potential crossreactivities were tested on a broad panel of human normal tissues.

RESULTS

The anti-PSMA mAbs showed a strong binding to C4-2 cells with mean half-maximal saturation concentrations of about 14 nM for 3/A12, 17 nM for 3/E7, 9 nM for 3/F11, and 16 nM for J591. Competitive binding studies revealed that our three mAbs bind to different extracellular PSMA epitopes. The mAbs showed comparable staining of epithelial cells for all tested normal and tumorous prostate tissues. Extraprostatic staining was observed on secretory cells of the salivary glands and on the brush border of the duodenal columnar epithelium. J591 additionally showed positive staining of the normal breast epithelium.

CONCLUSIONS

Due to their specific binding characteristics, the anti-PSMA mAbs 3/A12, 3/E7, and 3/F11 show great promise for diagnostic and therapeutic applications in prostate cancer.

摘要

背景

前列腺特异性膜抗原(PSMA)是一种很有吸引力的抗原,可用于前列腺癌的抗体诊断和治疗干预,因为它高度局限于前列腺,并且在所有肿瘤阶段都过度表达。本研究描述了三种抗 PSMA 单克隆抗体(mAb)3/A12、3/E7 和 3/F11 与 mAb J591 的体外特性。

方法

通过流式细胞术检测 mAb 在 C4-2 前列腺癌细胞上的饱和和竞争结合。对冷冻的前列腺正常和癌组织以及淋巴结转移进行免疫组织化学染色。同样,在广泛的人类正常组织面板上测试了潜在的交叉反应性。

结果

抗 PSMA mAb 与 C4-2 细胞具有很强的结合力,3/A12 的平均半最大饱和浓度约为 14 nM,3/E7 为 17 nM,3/F11 为 9 nM,J591 为 16 nM。竞争结合研究表明,我们的三种 mAb 结合到不同的 PSMA 细胞外表位。mAb 对所有测试的正常和肿瘤前列腺组织的上皮细胞均显示出相似的染色。在外分泌细胞的唾液腺和十二指肠柱状上皮的刷状缘上观察到额外的前列腺外染色。J591 还对正常乳腺上皮显示出阳性染色。

结论

由于其特异性结合特性,抗 PSMA mAb 3/A12、3/E7 和 3/F11 有望在前列腺癌的诊断和治疗应用中具有很大的潜力。

相似文献

1
Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.三种针对不同 PSMA 表位的构象抗体是前列腺癌有前途的诊断和治疗工具。
Prostate. 2010 Apr 1;70(5):562-9. doi: 10.1002/pros.21090.
2
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.新一代针对细胞黏附性前列腺特异性膜抗原的单克隆抗体和重组抗体,用于前列腺癌的诊断和治疗靶向。
Prostate. 2006 Sep 15;66(13):1359-70. doi: 10.1002/pros.20367.
3
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.前列腺特异性膜抗原细胞外结构域特异性放射性标记单克隆抗体的体外特性研究
Cancer Res. 2000 Sep 15;60(18):5237-43.
4
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.五种不同的抗前列腺特异性膜抗原(PSMA)抗体证实了PSMA在肿瘤相关新生血管中的表达。
Cancer Res. 1999 Jul 1;59(13):3192-8.
5
High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.采用三种不同的针对天然细胞黏附 PSMA 的 64Cu 标记抗体对前列腺癌异种移植进行高分辨率动物 PET 成像。
Prostate. 2010 Sep 15;70(13):1413-21. doi: 10.1002/pros.21176.
6
Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.新型单克隆抗体识别人类前列腺特异性膜抗原(PSMA)作为研究和诊疗工具。
Prostate. 2017 May;77(7):749-764. doi: 10.1002/pros.23311. Epub 2017 Mar 1.
7
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.用针对前列腺特异性膜抗原的铋 - 213标记J591抗体对人前列腺癌进行体外和临床前靶向α治疗。
Prostate Cancer Prostatic Dis. 2002;5(1):36-46. doi: 10.1038/sj.pcan.4500543.
8
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.针对前列腺特异性膜抗原细胞外结构域的放射性标记单克隆抗体:在携带LNCaP人前列腺肿瘤的裸鼠中的临床前研究
J Nucl Med. 2003 Apr;44(4):610-7.
9
Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.具有潜在临床应用价值的新型抗前列腺特异性膜抗原单克隆抗体的制备与表征
Hybridoma (Larchmt). 2007 Dec;26(6):363-72. doi: 10.1089/hyb.2007.0522.
10
Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).前列腺特异性膜抗原(PSMA)中存在的蛋白质构象表位特异性单克隆抗体的分离与鉴定。
Hybridoma. 2000 Jun;19(3):249-57. doi: 10.1089/02724570050109648.

引用本文的文献

1
Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.放射性免疫治疗在核医学中的最佳适应证:小型综述。
Curr Radiopharm. 2024;17(4):320-329. doi: 10.2174/0118744710295825240308093429.
2
Advances in PSMA theranostics.前列腺特异性膜抗原(PSMA)诊疗学的进展。
Transl Oncol. 2022 Aug;22:101450. doi: 10.1016/j.tranon.2022.101450. Epub 2022 May 18.
3
Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes.
前列腺特异性膜抗原通过调节精氨酸和脯氨酸的合成以及雄激素受体和 Fos 原癌基因的表达来调节前列腺癌的进展。
Bioengineered. 2022 Jan;13(1):995-1012. doi: 10.1080/21655979.2021.2016086.
4
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.在转移性去势抵抗性前列腺癌患者中,每四周接受三个周期 PSMA-617 治疗后肾脏和唾液腺功能。
Curr Oncol. 2021 Sep 23;28(5):3692-3704. doi: 10.3390/curroncol28050315.
5
The effect of eating on the uptake of PSMA ligands in the salivary glands.进食对唾液腺中PSMA配体摄取的影响。
EJNMMI Res. 2021 Sep 26;11(1):95. doi: 10.1186/s13550-021-00838-y.
6
Targeted Toxins for the Treatment of Prostate Cancer.用于治疗前列腺癌的靶向毒素
Biomedicines. 2021 Aug 9;9(8):986. doi: 10.3390/biomedicines9080986.
7
The potential of CAR T cell therapy for prostate cancer.嵌合抗原受体 T 细胞疗法治疗前列腺癌的潜力。
Nat Rev Urol. 2021 Sep;18(9):556-571. doi: 10.1038/s41585-021-00488-8. Epub 2021 Jul 8.
8
Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.胃肠道癌的 PET/CT 影像学表现及陷阱。
Semin Nucl Med. 2021 Sep;51(5):485-501. doi: 10.1053/j.semnuclmed.2021.04.001. Epub 2021 May 6.
9
Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine.使用格隆溴铵对唾液腺进行毒蕈碱抑制不会降低PSMA配体或放射性碘的摄取。
EJNMMI Res. 2021 Mar 12;11(1):25. doi: 10.1186/s13550-021-00770-1.
10
Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?在抑制剂部分进行修饰的PSMA配体设计:一种降低放射性标记PSMA抑制剂唾液腺摄取的方法?
EJNMMI Radiopharm Chem. 2021 Feb 26;6(1):10. doi: 10.1186/s41181-021-00124-1.